Cite
HARVARD Citation
van der Boor, S. et al. (2022). Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults. Lancet infectious diseases. 22 (11), pp. 1596-1605. [Online].